Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study

Biomed Res Int. 2015:2015:870987. doi: 10.1155/2015/870987. Epub 2015 Jan 29.

Abstract

Objective: To compare the efficacy of different therapies in the treatment of macular edema associated with retinal vein occlusion (RVO).

Design: This is a nonrandomized, multicenter collaborative study.

Participants: 86 retina specialists from 29 countries provided clinical information, including choice of treatment and outcome, on 2,603 patients with macular edema including 738 cases of RVO.

Methods: Reported data included the type and number of treatments performed, visual acuities, and other clinical and diagnostic findings.

Main outcome measures: The mean increase in visual acuity and mean number of treatments performed.

Results: 358 cases of central retinal vein occlusion (CRVO) and 380 cases of branch retinal vein occlusion (BRVO) were included in this investigation. Taking all RVO cases together, pars plana vitrectomy with internal limiting membrane (ILM) peeling alone resulted in an improvement in vision greater than other therapies. Those treated with intravitreal antivascular endothelial growth factor (anti-VEGF) injection alone showed the second greatest improvement in vision. Dexamethasone intravitreal implant alone and intravitreal triamcinolone alone both resulted in modest visual gains.

Conclusions: In the treatment of macular edema in RVO, vitrectomy with ILM peeling may achieve visual improvement and may be a good option for certain cases. Anti-VEGF injection is the most effective of the nonsurgical treatments.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Dexamethasone / administration & dosage
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy*
  • Macular Edema / pathology
  • Retinal Vein Occlusion / drug therapy*
  • Retinal Vein Occlusion / pathology
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Triamcinolone / administration & dosage
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / drug effects*
  • Vitrectomy

Substances

  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Triamcinolone
  • Bevacizumab
  • Dexamethasone